Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

NCT02031055 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: TAS-102 with a light tracer dose of [14C]FTD
DRUG: TAS-102 with a light tracer dose of [14C] TPI
DRUG: TAS-102 tablets

Sponsor

Taiho Oncology, Inc.